0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Clinical Challenges in Otolaryngology |

The Use of Genetic Markers in the Clinical Care of Patients With Head and Neck Cancer

Paul L. Friedlander, MD
Arch Otolaryngol Head Neck Surg. 2003;129(3):363-366. doi:10.1001/archotol.129.3.363.
Text Size: A A A
Published online

Extract

Hypothesis: Genetic markers are not currently useful in the clinical care of patients with head and neck cancer.

Parkin  DMLaara  EMuir  CS Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer.1988;41:184-197.
Swango  PA Cancers of the oral cavity and pharynx in the United States: an epidemiologic overview. J Public Health Dent.1996;56:309-318.
Quon  HLiu  FFCummings  BJ Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck.2001;23:147-159.
Smith  BDHaffty  BGSasaki  CT Molecular markers in head and neck squamous cell carcinoma: their biological function and prognostic significance. Ann Otol Rhinol Laryngol.2001;110:221-228.
Sakai  ETsuchida  N Most human squamous cell carcinomas in the oral cavity contain mutated p53 tumor-suppressor genes. Oncogene.1992;7:927-933.
Greenblatt  MSBennett  WPHollstein  MHarris  CC Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res.1994;54:4855-4878.
Klagsbrun  MD'Amore  PA Regulators of angiogenesis. Annu Rev Physiol.1991;53:217-239.
Salesiotis  ANCullen  KJ Molecular markers predictive of response and prognosis in the patient with advanced squamous cell carcinoma of the head and neck: evolution of a model beyond TNM staging. Curr Opin Oncol.2000;12:229-239.
Rowley  H The molecular genetics of head and neck cancer. J Laryngol Otol.1998;112:607-612.
Keene  SADemeure  MJ The clinical significance of micrometastases and molecular metastases. Surgery.2001;129:1-5.
Koch  WM Clinical implications of biomarkers in head and neck cancer. Curr Oncol Rep.1999;1:129-137.
de Bree  RDeurloo  EESnow  GBLeemans  CR Screening for distant metastases in patients with head and neck cancer. Laryngoscope.2000;110:397-401.
Dolan  RWVaughan  CWFuleihan  N Symptoms in early head and neck cancer: an inadequate indicator. Otolaryngol Head Neck Surg.1998;119:463-467.
Spafford  MFKoch  WMReed  AL  et al Detection of head and neck squamous cell carcinoma among exfoliated oral mucosal cells by microsatellite analysis. Clin Cancer Res.2001;7:607-612.
Fliss  MSUsadel  HCaballero  OL  et al Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science.2000;287:2017-2019.
van Houten  VMTabor  MPvan den Brekel  MW  et al Molecular assays for the diagnosis of minimal residual head-and-neck cancer: methods, reliability, pitfalls, and solutions. Clin Cancer Res.2000;6:3803-3816.
Nawroz  HKoch  WAnker  PStroun  MSidransky  D Microsatellite alterations in serum DNA of head and neck cancer patients. Nat Med.1996;2:1035-1037.
van Houten  VMvan den Brekel  MWDenkers  F  et al Molecular diagnosis of head and neck cancer. Recent Results Cancer Res.2000;157:90-106.
Brennan  JAMao  LHruban  RH  et al Molecular assessment of histopathological staging in squamous-cell carcinoma of the head and neck. N Engl J Med.1995;332:429-435.
Sturgis  EMMiller  RH Second primary malignancies in the head and neck cancer patient. Ann Otol Rhinol Laryngol.1995;104:946-954.
Hong  WKLippman  SMItri  LM  et al Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med.1990;323:795-801.
Papadimitrakopoulou  VAClayman  GLShin  DM  et al Biochemoprevention for dysplastic lesions of the upper aerodigestive tract. Arch Otolaryngol Head Neck Surg.1999;125:1083-1089.
Clayman  GLFrank  DKBruso  PAGoepfert  H Adenovirus-mediated wild-type p53 gene transfer as a surgical adjuvant in advanced head and neck cancers. Clin Cancer Res.1999;5:1715-1722.
Nemunaitis  JKhuri  FGanly  I  et al Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. J Clin Oncol.2001;19:289-298.
Gleich  LLGluckman  JLNemunaitis  J  et al Clinical experience with HLA-B7 plasmid DNA/lipid complex in advanced squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg.2001;127:775-779.
Dassonville  OFormento  JLFrancoual  M  et al Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol.1993;11:1873-1878.
Robert  FEzekiel  MPSpencer  SA  et al Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol.2001;19:3234-3243.
Shin  DMDonato  NJPerez-Soler  R  et al Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res.2001;7:1204-1213.
Figures in this Article

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

Figures

Place holder to copy figure label and caption

Paul L. Friedlander, MD

Graphic Jump Location

Tables

References

Correspondence

CME
Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Submit a Comment

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Web of Science® Times Cited: 9

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Collections
PubMed Articles
Jobs
JAMAevidence.com

Care at the Close of Life EDUCATION GUIDES
Palliative Care for Patients with Head and Neck Cancer

brightcove.createExperiences();